Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2288 Target Snapshot

Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 · SINGLE PROTEIN · Homo sapiens

36,317Compounds
160Assays
4Approved Drugs
734.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q13526. Use UniProt Q13526 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q13526 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 as ChEMBL target CHEMBL2288, mapped to UniProt Q13526. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2288
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13526
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 is the right protein anchor across sources, using UniProt Q13526 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPeptidyl-prolyl cis-trans isomerase NIMA-interacting 1
UniProt AccessionQ13526
Component TypeProtein
Sequence Length163 aa

Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1, mapped to UniProt Q13526. Sequence length is 163 aa.

Mapped IDQ13526
Review namePeptidyl-prolyl cis-trans isomerase NIMA-interacting 1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

4
Approved
1
Phase III
Assay Mix

Activity Type Distribution

IC50469.0
KI130.0
EC502.0
KD133.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL219531 8.92 Ki 1.2 Preclinical
CHEMBL5395865 8.92 Ki 1.2 Preclinical
CHEMBL438271 8.32 Ki 4.8 Preclinical
CHEMBL585917 8.22 IC50 6.0 Preclinical
CHEMBL1090715 8.22 Ki 6.0 Preclinical
CHEMBL1089602 8.22 Ki 6.0 Preclinical
CHEMBL585917 8.22 Ki 6.0 Preclinical
CHEMBL1163019 8.1 Ki 8.0 Preclinical
CHEMBL3353369 7.92 Ki 12.0 Preclinical
CHEMBL4750217 7.82 Ki 15.0 Preclinical
Distribution

pChEMBL Value Distribution

131
5.0
112
5.5
92
6.0
45
6.5
24
7.0
15
7.5
7
8.0
2
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

TRETINOIN
CHEMBL38
Approved 1971
Assay Landscape

Assay Landscape

160
Total Assays
519
Tested Compounds
2
Assay Types
Binding — 156 assays, 519 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 93 322 5.6
cell-based format 35 1 4.8
assay format 28 196 5.6
Functional — 4 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 4 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine